Eli Lilly slashes obesity drug price by up to 20% [Los Angeles Times (CA)]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Los Angeles Times
Starting Monday, the lowest dose vial will cost $299 a month for those who pay cash, Lilly said in a statement, a discount of about $50. The next higher dose will cost $399 a month, roughly 20% less than the previous self-pay price. Lilly isn't changing the price of higher doses, which are sold for $499 a month. It's the latest move in a price war with Denmark's Novo Nordisk, which is making it significantly less expensive for people to start the blockbuster medicines. Novo cut its cash-pay prices in November. Introductory doses for its Ozempic and Wegovy are now $199 for the first two months on the NovoCare direct-to-consumer portal, then rise to $349 a month. Lilly's discounts are available through the company's direct-to-consumer portal, LillyDirect. Patients typically start at lower doses, before moving to higher strengths for more weight loss. Ilya Yuffa, president of Lilly USA, said the discounts underscore the company's commitment to improving access to obesity care. It'
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Hims and Hers acquires Livewell ahead of generic Ozempic launch in Canada [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk A/S (NYSE:NVO) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer's, despite trial setback [MSNBC.com]MSNBC.com
- Novo Nordisk A/S (NVO): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website